Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | AKT2 | P31751 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510357 | 0.87 | ADORA3 (0.42) | ADORA3BRD4 | |
| SCHEMBL22326718 | 0.81 | ADORA3 (0.39) | ADORA3BRD4 | |
| SCHEMBL18519546 | 0.74 | ADORA3 (0.44) | ADORA3BRD4AKT1AKT2 | |
| SCHEMBL21137626 | 0.70 | ADORA3 (0.42) | ADORA3BRD4 | |
| SCHEMBL24236941 | 0.70 | ADORA3 (0.42) | ADORA3BRD4AKT1AKT2 | |
| SCHEMBL23476796 | 0.70 | ADORA3 (0.42) | ADORA3BRD4 | |
| SCHEMBL21539430 | 0.70 | ADORA3 (0.42) | ADORA3BRD4AKT1AKT2 | |
| SCHEMBL23619260 | 0.70 | ADORA3 (0.42) | ADORA3BRD4 | |
| SCHEMBL17674862 | 0.68 | GRIN2D (0.41) | ADORA3BRD4 | |
| SCHEMBL24968165 | 0.62 | PDE9A (0.39) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11376272-B2 | Methods of modulating immune activity | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210299155-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| US-10980825-B2 | Cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | STING1, IRF3, CGAS | ADORA3 37/4885BRD4 2064/4885AKT1 1671/4885 |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | ADORA3 579/4885BRD4 2312/4885AKT1 2404/4885 |
| US-20210137962-A9 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | ADORA3 648/4885BRD4 2126/4885AKT1 1584/4885 |
| US-10980825-B2 | Cyclic dinucleotide | STING1, CGAS, MAVS | ADORA3 648/4885BRD4 2126/4885AKT1 1584/4885 |
| US-20190192549-A1 | CYCLIC DINUCLEOTIDE | STING1, CGAS, MAVS | ADORA3 648/4885BRD4 2126/4885AKT1 1584/4885 |
| US-20210299155-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | STING1, IRF3, CGAS | ADORA3 38/4885BRD4 2551/4885AKT1 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.